ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone

Study limitation reported by the research below: “Cost savings are modeled hypothetically using 2024 U.S. Medicare rates and do not include geographic variation, clinician time, downstream treatment costs, or the economic consequences of misclassification including ARIA risk from false-positive DMT eligibility.”

Papers